Logo image of CRMD

CORMEDIX INC (CRMD) Stock Fundamental Analysis

USA - NASDAQ:CRMD - US21900C3088 - Common Stock

11.245 USD
+0.04 (+0.4%)
Last: 10/23/2025, 1:37:48 PM
Fundamental Rating

7

CRMD gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. CRMD has an excellent financial health rating, but there are some minor concerns on its profitability. CRMD is growing strongly while it also seems undervalued. This is an interesting combination These ratings could make CRMD a good candidate for value and growth investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

CRMD had positive earnings in the past year.
In the past year CRMD had a positive cash flow from operations.
In the past 5 years CRMD always reported negative net income.
CRMD had a negative operating cash flow in each of the past 5 years.
CRMD Yearly Net Income VS EBIT VS OCF VS FCFCRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

CRMD has a better Return On Assets (20.25%) than 97.38% of its industry peers.
CRMD has a Return On Equity of 23.19%. This is amongst the best in the industry. CRMD outperforms 93.72% of its industry peers.
With an excellent Return On Invested Capital value of 17.64%, CRMD belongs to the best of the industry, outperforming 94.76% of the companies in the same industry.
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROIC 17.64%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
CRMD Yearly ROA, ROE, ROICCRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

With an excellent Profit Margin value of 42.11%, CRMD belongs to the best of the industry, outperforming 97.91% of the companies in the same industry.
With an excellent Operating Margin value of 40.60%, CRMD belongs to the best of the industry, outperforming 97.38% of the companies in the same industry.
Looking at the Gross Margin, with a value of 95.62%, CRMD belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
CRMD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
CRMD Yearly Profit, Operating, Gross MarginsCRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K

More info and screens

8

2. Health

2.1 Basic Checks

CRMD has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CRMD has been increased compared to 1 year ago.
CRMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRMD Yearly Shares OutstandingCRMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRMD Yearly Total Debt VS Total AssetsCRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 16.19 indicates that CRMD is not in any danger for bankruptcy at the moment.
CRMD has a better Altman-Z score (16.19) than 88.48% of its industry peers.
There is no outstanding debt for CRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 16.19
ROIC/WACC2.03
WACC8.71%
CRMD Yearly LT Debt VS Equity VS FCFCRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M 80M

2.3 Liquidity

CRMD has a Current Ratio of 7.82. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRMD (7.82) is better than 76.44% of its industry peers.
CRMD has a Quick Ratio of 7.52. This indicates that CRMD is financially healthy and has no problem in meeting its short term obligations.
CRMD's Quick ratio of 7.52 is fine compared to the rest of the industry. CRMD outperforms 75.39% of its industry peers.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.52
CRMD Yearly Current Assets VS Current LiabilitesCRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

8

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 180.65% over the past year.
CRMD shows a strong growth in Revenue. In the last year, the Revenue has grown by 14970.65%.
CRMD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 174.29% yearly.
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%

3.2 Future

Based on estimates for the next years, CRMD will show a very strong growth in Earnings Per Share. The EPS will grow by 57.72% on average per year.
CRMD is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.43% yearly.
EPS Next Y590.65%
EPS Next 2Y201.92%
EPS Next 3Y113.37%
EPS Next 5Y57.72%
Revenue Next Year525.46%
Revenue Next 2Y216.16%
Revenue Next 3Y120.01%
Revenue Next 5Y63.43%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CRMD Yearly Revenue VS EstimatesCRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 200M 400M 600M
CRMD Yearly EPS VS EstimatesCRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 14.99, CRMD is valued correctly.
CRMD's Price/Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 85.86% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.57. CRMD is valued slightly cheaper when compared to this.
Based on the Price/Forward Earnings ratio of 4.79, the valuation of CRMD can be described as very cheap.
CRMD's Price/Forward Earnings ratio is rather cheap when compared to the industry. CRMD is cheaper than 95.81% of the companies in the same industry.
CRMD is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.09, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 14.99
Fwd PE 4.79
CRMD Price Earnings VS Forward Price EarningsCRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

85.34% of the companies in the same industry are more expensive than CRMD, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRMD indicates a rather cheap valuation: CRMD is cheaper than 81.15% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.6
EV/EBITDA 12.32
CRMD Per share dataCRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CRMD has a very decent profitability rating, which may justify a higher PE ratio.
CRMD's earnings are expected to grow with 113.37% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y201.92%
EPS Next 3Y113.37%

More info and screens

0

5. Dividend

5.1 Amount

CRMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORMEDIX INC

NASDAQ:CRMD (10/23/2025, 1:37:48 PM)

11.245

+0.04 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners46.71%
Inst Owner Change0.6%
Ins Owners7.55%
Ins Owner Change4.38%
Market Cap839.44M
Revenue(TTM)121.48M
Net Income(TTM)51.16M
Analysts81.54
Price Target20.91 (85.95%)
Short Float %24.21%
Short Ratio4.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.96%
Min EPS beat(2)13.12%
Max EPS beat(2)58.8%
EPS beat(4)4
Avg EPS beat(4)44.57%
Min EPS beat(4)13.12%
Max EPS beat(4)58.8%
EPS beat(8)7
Avg EPS beat(8)23.17%
EPS beat(12)8
Avg EPS beat(12)15.69%
EPS beat(16)11
Avg EPS beat(16)13.24%
Revenue beat(2)2
Avg Revenue beat(2)9.08%
Min Revenue beat(2)3.69%
Max Revenue beat(2)14.48%
Revenue beat(4)4
Avg Revenue beat(4)9.28%
Min Revenue beat(4)3.62%
Max Revenue beat(4)15.32%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.65%
PT rev (3m)25%
EPS NQ rev (1m)6.39%
EPS NQ rev (3m)81.83%
EPS NY rev (1m)15.01%
EPS NY rev (3m)57.39%
Revenue NQ rev (1m)7.44%
Revenue NQ rev (3m)65.11%
Revenue NY rev (1m)6.23%
Revenue NY rev (3m)53.19%
Valuation
Industry RankSector Rank
PE 14.99
Fwd PE 4.79
P/S 6.91
P/FCF 27.6
P/OCF 27.56
P/B 3.8
P/tB 3.83
EV/EBITDA 12.32
EPS(TTM)0.75
EY6.67%
EPS(NY)2.35
Fwd EY20.88%
FCF(TTM)0.41
FCFY3.62%
OCF(TTM)0.41
OCFY3.63%
SpS1.63
BVpS2.96
TBVpS2.93
PEG (NY)0.03
PEG (5Y)N/A
Graham Number7.06
Profitability
Industry RankSector Rank
ROA 20.25%
ROE 23.19%
ROCE 22.33%
ROIC 17.64%
ROICexc 129.11%
ROICexgc 137.01%
OM 40.6%
PM (TTM) 42.11%
GM 95.62%
FCFM 25.03%
ROA(3y)-39.81%
ROA(5y)-41%
ROE(3y)-47.06%
ROE(5y)-47.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y63.88%
GM growth 5YN/A
F-Score7
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 10.02%
Cap/Sales 0.04%
Interest Coverage 1343.8
Cash Conversion 61.11%
Profit Quality 59.44%
Current Ratio 7.82
Quick Ratio 7.52
Altman-Z 16.19
F-Score7
WACC8.71%
ROIC/WACC2.03
Cap/Depr(3y)258.21%
Cap/Depr(5y)648.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)180.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%212%
EPS Next Y590.65%
EPS Next 2Y201.92%
EPS Next 3Y113.37%
EPS Next 5Y57.72%
Revenue 1Y (TTM)14970.65%
Revenue growth 3Y511.63%
Revenue growth 5Y174.29%
Sales Q2Q%4829.39%
Revenue Next Year525.46%
Revenue Next 2Y216.16%
Revenue Next 3Y120.01%
Revenue Next 5Y63.43%
EBIT growth 1Y184.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year651.77%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y197%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y197.89%
OCF growth 3YN/A
OCF growth 5YN/A